Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease

Document Type

Article

Publication Date

6-13-2020

Publication Title

The Annals of pharmacotherapy

Abstract

Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection.

PubMed ID

32536199

ePublication

ePub ahead of print

Find It @ Sladen

Share

COinS